Key result
Daily caffeine consumption was associated with a significantly lower incidence of chest pain (10% vs 45%) and aminophylline administration during regadenoson stress testing compared to non-consumers.
Why the study?
Caffeine is typically withheld before regadenoson stress, but the effects of daily caffeine intake on regadenoson stress testing were unknown.
Does daily caffeine consumption reduce the incidence of symptoms and hemodynamic changes during regadenoson pharmacologic stress testing in patients undergoing myocardial perfusion imaging?
Population
101 patients presenting for regadenoson stress myocardial perfusion imaging
Comparison
Daily caffeine intake categories (<200, 200-400, and >400 mg daily) vs no caffeine use
Design
Observational cohort study
Authors
Loading...
May lessen symptoms during regadenoson stress testing; leaves open whether to alter pre-test caffeine instructions pending randomized data.
Observational (n=101)
No
Does daily caffeine consumption reduce the incidence of symptoms and hemodynamic changes during regadenoson pharmacologic stress testing in patients undergoing myocardial perfusion imaging?
Absolute Event Rate: 10% vs 45%
p-value: p=0.0013
Daily caffeine consumption is safe and associated with fewer adverse symptoms, specifically chest pain, and a reduced need for aminophylline reversal during regadenoson stress testing.
Posch et al. (2019) conducted an observational in Patients undergoing pharmacologic stress testing with regadenoson (n=101). Daily caffeine consumption vs. No daily caffeine consumption was evaluated on Chest pain (p=0.0013). Daily caffeine consumption was associated with a significantly lower incidence of chest pain (10% vs 45%) and aminophylline administration during regadenoson stress testing compared to non-consumers.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: